Why biotech is fast becoming the story of 2012

Professional investors are piling into biotech stocks - and hoping you won't notice, says Tom Bulford. So, don't miss out on what’s fast becoming the investment story of the year.

Gentlemen! We are all afraid of prostate cancer, are we not? And all the more so because the doctor could recommend the ultimate remedy castration! But even that may not be enough. Some cancers are resistant to castration.

But now there is hope, thanks to MDV3100 a drug that has been shown to extend the life of prostate sufferers. It's the lead product of Medivation (Nasdaq: MDVN) which has seen its share price quadruple over the last year.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Explore More

Tom worked as a fund manager in the City of London and in Hong Kong for over 20 years. As a director with Schroder Investment Management International he was responsible for £2 billion of foreign clients' money, and launched what became Argentina's largest mutual fund. Now working from his home in Oxfordshire, Tom Bulford helps private investors with his premium tipping newsletter, Red Hot Biotech Alert.